Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms

Cancer Research

Volumn 73, Issue 13, 2013, Pages 3877-3887

  Mao, Yumeng ^a   Poschke, Isabel ^a,b   Wennerberg, Erik ^a   De Coaña, Yago Pico ^a   Brage, Suzanne Egyhazi ^a   Schultz, Inkeri ^a   Hansson, Johan ^a   Masucci, Giuseppe ^a   Lundqvist, Andreas ^a   Kiessling, Rolf ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CYCLOOXYGENASE 2; GAMMA INTERFERON; PROSTAGLANDIN E2; STAT3 PROTEIN; SUPEROXIDE;

ADVANCED CANCER; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MELANOMA; MELANOMA CELL; MONOCYTE; MYELOID DERIVED SUPPRESSOR CELL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

ANTIGENS, CD; ANTIGENS, CD14; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYCLOOXYGENASE 2; DINOPROSTONE; HLA-DR ANTIGENS; HUMANS; IMMUNE TOLERANCE; LEUKOCYTES, MONONUCLEAR; MELANOMA; MYELOID CELLS; PHENOTYPE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; UP-REGULATION;

EID: 84880072604     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4115     Document Type: Article

References (45)

1. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9: 162-74.
2. Munera V, Popovic PJ, Bryk J, Pribis J, Caba D, Matta BM, et al. Stat 6- dependent induction of myeloid-derived suppressor cells after physical injury regulates nitric oxide response to endotoxin. Ann Surg 2010;251: 120-6.
3. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cellsuppressive activity. Blood 2008;111: 4233-44.
4. Poschke I, Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol 2012;144: 250-68.
5. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011;32: 19-25.
6. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloidderived suppressor cells in tumor-bearing mice. J Immunol 2008;181: 5791-802.
7. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010;70: 4335-45.
8. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007;25: 2546-53.
9. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009;182: 4499-506.
10. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid-derived suppressor cells. Immunol Rev 2008;222: 162-79.
11. Kusmartsev S, Gabrilovich DI. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 2006;25: 323-31.
12. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117: 1175-83.
13. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokineinduced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010;185: 2273-84.
14. Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 2011;118: 2254-65.
15. Lechner MG, Megiel C, Russell SM, Bingham B, Arger N, Woo T, et al. Functional characterization of human Cd33+ and Cd11b+ myeloidderived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med 2011;9: 90.
16. Rodrigues JC, Gonzalez GC, Zhang L, Ibrahim G, Kelly JJ, Gustafson MP, et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol 2010;12: 351-65.
17. Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011;118: 5498-505.
18. Cryan LM, Paraoan L, Hiscott P, Damato BE, Grierson I, Gray D, et al. Expression of COX-2 and prognostic outcome in uveal melanoma. Curr Eye Res 2008;33: 177-84.
19. Johansson CC, Egyhazi S, Masucci G, Harlin H, Mougiakakos D, Poschke I, et al. Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma. Cancer Immunol Immunother 2009;58: 1085-94.
20. Obermajer N, Wong JL, Edwards RP, Odunsi K, Moysich K, Kalinski P. PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunol Invest 2012;41: 635-57.
21. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007;67: 4507-13.
22. Gorgun GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, et al. Tumor promoting immune-suppressive myeloidderived suppressor cells in the multiple myeloma microenvironment in humans. Blood 2013;121: 2975-87.
23. Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin Cancer Res 2012;18: 5212-23.
24. Hallermalm K, De Geer A, Kiessling R, Levitsky V, Levitskaya J. Autocrine secretion of Fas ligand shields tumor cells from Fasmediated killing by cytotoxic lymphocytes. Cancer Res 2004;64: 6775-82.
25. Selvan SR, Carbonell DJ, Fowler AW, Beatty AR, Ravindranath MH, Dillman RO. Establishment of stable cell lines for personalized melanoma cell vaccine. Melanoma Res 2010;20: 280-92.
26. Han C, Demetris AJ, Stolz DB, Xu L, Lim K, Wu T. Modulation of Stat3 activation by the cytosolic phospholipase A2alpha and cyclooxygenase- 2-controlled prostaglandin E2 signaling pathway. J Biol Chem 2006;281: 24831-46.
27. Yang R, Cai Z, Zhang Y, Yutzy WHt, Roby KF, Roden RB. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr- 1+CD11b+ myeloid cells. Cancer Res 2006;66: 6807-15.
28. Mencacci A, Montagnoli C, Bacci A, Cenci E, Pitzurra L, Spreca A, et al. CD80+Gr-1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis. J Immunol 2002;169: 3180-90.
29. Liu Y, Yu Y, Yang S, Zeng B, Zhang Z, Jiao G, et al. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol Immunother 2009;58: 687-97.
30. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5: 1365-9.
31. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192: 1027-34.
32. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010;37: 508-16.
33. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24: 207-12.
34. Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P. PGE (2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 2011;71: 7463-70.
35. Denkert C, Kobel M, Berger S, Siegert A, Leclere A, Trefzer U, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001;61: 303-8.
36. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009;182: 5693-701.
37. Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg AA, Sebti SM, et al. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol 2005;175: 4338-46.
38. FortinCF, Larbi A, Dupuis G, Lesur O, Fulop T Jr.GM-CSF activates the Jak/STAT pathway to rescue polymorphonuclear neutrophils from spontaneous apoptosis in young but not elderly individuals. Biogerontology 2007;8: 173-87.
39. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005;41: 2502-12.
40. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. Highdose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004;64: 6337-43.
41. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012;21: 822-35.
42. Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 2012;21: 836-47.
43. Poschke I, Mao Y, Adamson L, Salazar-Onfray F, Masucci G, Kiessling R. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol Immunother 2012;61: 827-38.
44. Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 2001;167: 2831-8.
45. Obermajer N, Kalinski P. Generation of myeloid-derived suppressor cells using prostaglandin E2. Transplant Res 2012;1: 15.